Investigational drug · Phase 3
Tinlarebant
Also called: LBS-008
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Stargardt Disease 1, STGD1, Geographic Atrophy.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
5
Any phase or sponsor naming "Tinlarebant"
First trial start
2022
Mar 28, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tinlarebant", any sponsor or status.
Conditions studied
As listed on its trial records.
- Stargardt Disease 1
- STGD1
- Geographic Atrophy
Approved drugs for the same conditions: Geographic atrophy
Largest trials
Live from ClinicalTrials.gov: studies naming "Tinlarebant" as an intervention, largest first.
- Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic AtrophyPivotal-lookingActive, not recruiting
Belite Bio, IncIndustry
NCT05949593 · 429 participants (planned) · Start Jul 27, 2023 · Primary completion Jun 30, 2027
Drug: Tinlarebant; Placebo · For: Geographic Atrophy
Sites: Phoenix, Arizona; Arcadia, California; Beverly Hills, California · 49 sites in all
- Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt DiseasePivotal-lookingCompleted
Belite Bio, IncIndustry
NCT05244304 · 104 participants · Start Mar 28, 2022 · Primary completion Aug 4, 2025
Drug: Tinlarebant; Placebo · For: Stargardt Disease 1
Sites: Palo Alto, California; Minneapolis, Minnesota; Salt Lake City, Utah · 19 sites in all
- A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt DiseasePivotal-lookingActive, not recruiting
Belite Bio, IncIndustry
NCT06388083 · 60 participants (planned) · Start Jul 31, 2024 · Primary completion Feb 2028
Drug: Tinlarebant; Placebo · For: STGD1; Stargardt Disease 1
Sites: Phoenix, Arizona; La Jolla, California; San Francisco, California · 18 sites in all
RBP4 Pty LtdIndustry
NCT05667688 · 15 participants · Start Nov 28, 2022 · Primary completion Jan 4, 2023
Drug: Tinlarebant (LBS-008) · For: Healthy Volunteer; Dry Age-related Macular Degeneration
Sites: Melbourne, Australia
RBP4 Pty LtdIndustry
NCT05266014 · 13 participants · Start Mar 12, 2021 · Primary completion Aug 15, 2023
Drug: tinlarebant · For: Stargardt Disease
Sites: Westmead, Australia; Perth, Australia; Taipei, Taiwan
Newest research
PubMed records naming it or its code names, newest first.
- Structural and biochemical basis for retinol-binding protein 4 antagonism by tinlarebant.
Bassetto M, Kiser PD · Br J Pharmacol 2026
- Effects of Gastric Acid Suppression, Cytochrome P4503A Inhibition and Induction, and Food on the Pharmacokinetics of Tinlarebant in Healthy Adults.
Polasek TM, Paneliya KJ, Lin T, et al. · Clin Pharmacol Drug Dev 2026
- Stargardt's Disease: Molecular Pathogenesis and Current Therapeutic Landscape.
Dayma K, Rajanala K, Upadhyay A · Int J Mol Sci 2025
- Retinol binding protein 4 antagonists and protein synthesis inhibitors: Potential for therapeutic development.
Kim N, Priefer R · Eur J Med Chem 2021
Also in development for Stargardt Disease 1
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.